Raymond James Financial Inc. Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 456,774 shares of the biopharmaceutical company's stock, valued at approximately $21,838,000. Raymond James Financial Inc. owned approximately 0.36% of Halozyme Therapeutics at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $29,000. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics during the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,200 shares of company stock valued at $1,286,568. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Down 0.1 %

Shares of HALO opened at $58.79 on Friday. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The stock has a market capitalization of $7.26 billion, a P/E ratio of 17.14, a P/E/G ratio of 0.42 and a beta of 1.32. The business's 50-day moving average price is $60.42 and its 200 day moving average price is $55.02.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.